TY - JOUR
T1 - Biomarker analysis beyond angiogenesis
T2 - RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study
AU - Yoshino, T.
AU - Portnoy, D. C.
AU - Obermannová, R.
AU - Bodoky, G.
AU - Prausová, J.
AU - Garcia-Carbonero, R.
AU - Ciuleanu, T.
AU - García-Alfonso, P.
AU - Cohn, A. L.
AU - Van Cutsem, E.
AU - Yamazaki, K.
AU - Lonardi, S.
AU - Muro, K.
AU - Kim, T. W.
AU - Yamaguchi, K.
AU - Grothey, A.
AU - O'Connor, J.
AU - Taieb, J.
AU - Wijayawardana, S. R.
AU - Hozak, R. R.
AU - Nasroulah, F.
AU - Tabernero, J.
N1 - Publisher Copyright:
© The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Background:: Second-line treatment with ramucirumabþFOLFIRI improved overall survival (OS) versus placeboþFOLFIRI for patients with metastatic colorectal carcinoma (CRC) [hazard ratio (HR)¼0.84, 95% CI 0.73-0.98, P ¼ 0.022]. Post hoc analyses of RAISE patient data examined the association of RAS/RAF mutation status and the anatomical location of the primary CRC tumour (left versus right) with efficacy parameters. Patients and methods: Patient tumour tissue was classified as BRAF mutant, KRAS/NRAS (RAS) mutant, or RAS/BRAF wild-type. Left-CRC was defined as the splenic flexure, descending and sigmoid colon, and rectum; right-CRC included transverse, ascending colon, and cecum. Results: RAS/RAF mutation status was available for 85% of patients (912/1072) and primary tumour location was known for 94.4% of patients (1012/1072). A favourable and comparable ramucirumab treatment effect was observed for patients with RAS mutations (OS HR ¼ 0.86, 95% CI 0.71-1.04) and patients with RAS/BRAF wild-type tumours (OS HR ¼ 0.86, 95% CI 0.64-1.14). Among the 41 patients with BRAF-mutated tumours, the ramucirumab benefit was more notable (OS HR ¼ 0.54, 95% CI 0.25-1.13), although, as with the other genetic sub-group analyses, differences were not statistically significant. Progression-free survival (PFS) data followed the same trend. Treatment-by-mutation status interaction tests (OS P ¼ 0.523, PFS P ¼ 0.655) indicated that the ramucirumab benefit was not statistically different among the mutation sub-groups, although the small sample size of the BRAF group limited the analysis. Addition of ramucirumab to FOLFIRI improved left-CRC median OS by 2.5 month over placebo (HR ¼ 0.81, 95% CI 0.68-0.97); median OS for ramucirumab-treated patients with right-CRC was 1.1 month over placebo (HR ¼ 0.97, 95% CI 0.75-1.26). The treatment-by-sub-group interaction was not statistically significant for tumour sidedness (P ¼ 0.276). Conclusions: In the RAISE study, the addition of ramucirumab to FOLFIRI improved patient outcomes, regardless of RAS/RAF mutation status, and tumour sidedness. Ramucirumab treatment provided a numerically substantial benefit in BRAF-mutated tumours, although the P-values were not statistically significant.
AB - Background:: Second-line treatment with ramucirumabþFOLFIRI improved overall survival (OS) versus placeboþFOLFIRI for patients with metastatic colorectal carcinoma (CRC) [hazard ratio (HR)¼0.84, 95% CI 0.73-0.98, P ¼ 0.022]. Post hoc analyses of RAISE patient data examined the association of RAS/RAF mutation status and the anatomical location of the primary CRC tumour (left versus right) with efficacy parameters. Patients and methods: Patient tumour tissue was classified as BRAF mutant, KRAS/NRAS (RAS) mutant, or RAS/BRAF wild-type. Left-CRC was defined as the splenic flexure, descending and sigmoid colon, and rectum; right-CRC included transverse, ascending colon, and cecum. Results: RAS/RAF mutation status was available for 85% of patients (912/1072) and primary tumour location was known for 94.4% of patients (1012/1072). A favourable and comparable ramucirumab treatment effect was observed for patients with RAS mutations (OS HR ¼ 0.86, 95% CI 0.71-1.04) and patients with RAS/BRAF wild-type tumours (OS HR ¼ 0.86, 95% CI 0.64-1.14). Among the 41 patients with BRAF-mutated tumours, the ramucirumab benefit was more notable (OS HR ¼ 0.54, 95% CI 0.25-1.13), although, as with the other genetic sub-group analyses, differences were not statistically significant. Progression-free survival (PFS) data followed the same trend. Treatment-by-mutation status interaction tests (OS P ¼ 0.523, PFS P ¼ 0.655) indicated that the ramucirumab benefit was not statistically different among the mutation sub-groups, although the small sample size of the BRAF group limited the analysis. Addition of ramucirumab to FOLFIRI improved left-CRC median OS by 2.5 month over placebo (HR ¼ 0.81, 95% CI 0.68-0.97); median OS for ramucirumab-treated patients with right-CRC was 1.1 month over placebo (HR ¼ 0.97, 95% CI 0.75-1.26). The treatment-by-sub-group interaction was not statistically significant for tumour sidedness (P ¼ 0.276). Conclusions: In the RAISE study, the addition of ramucirumab to FOLFIRI improved patient outcomes, regardless of RAS/RAF mutation status, and tumour sidedness. Ramucirumab treatment provided a numerically substantial benefit in BRAF-mutated tumours, although the P-values were not statistically significant.
KW - BRAF
KW - Colorectal carcinoma
KW - KRAS
KW - Left
KW - NRAS
KW - Ramucirumab
UR - http://www.scopus.com/inward/record.url?scp=85060163908&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060163908&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdy461
DO - 10.1093/annonc/mdy461
M3 - Article
C2 - 30339194
AN - SCOPUS:85060163908
SN - 0923-7534
VL - 30
SP - 124
EP - 131
JO - Annals of Oncology
JF - Annals of Oncology
IS - 1
ER -